Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Other Financing Activities
Financing cash flows not reported separately.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities outflow grows to $0
Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $62.34M.
Context
- Other financing activities amounted to 623.4% of revenue in FY2025, up 502.2 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $15.58M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 62.34M USD
- Year-over-year change
- +1128.8%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.34M | +1128.8% |
| FY2024 | 2024-12-31 | (6.06M) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Financing Activities vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 other financing activities of $62.34M is the largest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of +1212.9% is the highest of 7, against a peer median of +212.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $62.34M | +1212.9% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $30.01M | — | — | — |
| LTM Sep 2026 | $7.96M | +1201.3% | — | 112.2% | |
| LTM Mar 2026 | $5.84M | +828.0% | — | 69.8% | |
| LTM Mar 2026 | $273K | +325.6% | — | — | |
| FY2025 | $196K | -791.9% | +63.5% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding ZBIO) | $0 | +212.8% | +63.5% | 34.9% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.